Looking for Body Chemistry Patterns in Atrial Fibrillation
Describes metabolic changes over time in adults with atrial fibrillation needing ablation.
Plain-language title generated from the registry record
Registry title: Identification of the Metabolic Signature of Atrial Fibrillation for Personalized Prevention
Key facts
- Where
- Pessac, FranceSee the site
Where in France
- University Hospital of BordeauxPessac, FranceTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- University Hospital, Bordeaux
- Trial code
- NCT06735001
- Record updated
- 9 June 2026
- Original description
Atrial fibrillation (AF) is a major public health problem. The efficacy of the existing techniques is limited in the more aggressive forms. It is therefore necessary to develop approaches, in particular the identification of relevant biomarkers, to prevent the onset, recurrence or progression of AF in at-risk patients. The objective of this study is to describe the longitudinal metabolic and biomolecular signature of AF in patients eligible for cardiac ablation.Read full original descriptionShow less
Identification of the Metabolic Signature of Atrial Fibrillation for Personalized Prevention
Atrial fibrillation (AF) is a major public health problem. The efficacy of the existing techniques is limited in the more aggressive forms. It is therefore necessary to develop approaches, in particular the identification of relevant biomarkers, to prevent the onset, recurrence or progression of AF in at-risk patients. The objective of this study is to describe the longitudinal metabolic and biomolecular signature of AF in patients eligible for cardiac ablation.
Inclusion: Age ≥ 18 years, all genders, and ethnic origins; Free, informed, and written consent signed; Person affiliated to or benefiting from a social security scheme.
Exclusion: Active tumor pathology (benign or malignant); Chronic inflammation or autoimmune disease; Chronic liver disease; Myocardial infarction within the last 8 weeks; Age < 18 years; Lack of informed consent; Gestating women (pregnancy test carried out as part of care for FA patients, contraception, or menopause for women in control groups); Persons under administrative or judicial protection; Endocarditis or pericarditis in progress or within the 3 last months.